论文部分内容阅读
采用酶免疫法（ＥＬＩＳＡ）对前列腺癌及其他疾病患者血清样本中的前列腺特异性抗原（ＰＳＡ）进行测定。同时比较了３８例前列腺癌患者血清中前列腺酸性磷酸酶（ＰＡＰ）和ＰＳＡ的水平。实验：结果表明前列腺癌患者血清ＰＳＡ阳性率为６８．５％，特异性为９６．７％，灵敏度高于血清ＰＡＰ。血清ＰＳＡ水平动态监测有助于临床判断前列腺癌的进程、预后及疗效。ＰＳＡ是一种有应用价值的前列腺癌肿瘤标记物。
Enzyme immunoassay (ELISA) was used to measure prostate-specific antigen (PSA) in serum samples from patients with prostate cancer and other diseases. The levels of serum prostatic acid phosphatase (PAP) and PSA in 38 patients with prostate cancer were also compared. Experiment: The results showed that the positive rate of PSA in serum of patients with prostate cancer was 68.5%, the specificity was 96.7%, and the sensitivity was higher than that of serum PAP. The dynamic monitoring of serum PSA level is helpful for clinical judgment of the progress, prognosis and curative effect of prostate cancer. PSA is a valuable prostate cancer tumor marker.